Mark S. Lesney, PhD

News

Choosing the right R-CHOP dosage for elderly patients with DLBCL

Author:: Mark S. Lesney, PhD

Publish date: June 8, 2021

Systemic review finds 80 years of age an important cutoff point for switching dosage.

News

Elevated factor VIII troughs can lead to a higher proportion of zero bleeds in hemophilia

Author:: Mark S. Lesney, PhD

Publish date: June 1, 2021

Rurioctocog alfa pegol prophylaxis to target 8%-12% FVIII troughs resulted in a higher proportion of people with...

News

High-dose methotrexate of no CNS benefit for patients with high-risk DLBCL

Author:: Mark S. Lesney, PhD

Publish date: May 18, 2021

A study showed the CNS relapse rate of patients with high-risk diffuse large B-cell lymphoma was not...

News

FDA approves new treatment option for rare anemia

Author:: Mark S. Lesney, PhD

Publish date: May 18, 2021

Pegcetacoplan (Empaveli) was approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH).

News

Health costs over 25 times higher for hemophilia B patients than controls

Author:: Mark S. Lesney, PhD

Publish date: May 11, 2021

Across four clinical profile categories, all-cause total costs, medical costs, and pharmacy costs were...

News

High variability found in studies assessing hemophilia-related pain

Author:: Mark S. Lesney, PhD

Publish date: May 4, 2021

There is high variability in hemophilia chronic pain definitions, samples, and assessment methods, as well as a...

News

Mitochondrial DNA predicts survival in pediatric acute myeloid leukemia

Author:: Mark S. Lesney, PhD

Publish date: April 23, 2021

Genetic analysis showed that the mitochondrial biogenesis gene PGC1A may have a possible role in increasing...

News

Predicting outcomes in therapy-related AML

Author:: Mark S. Lesney, PhD

Publish date: April 22, 2021

Among t-AML patients who underwent HSCT, a significant decrease in survival was associated with an increasing...

News

CLL patients: Diagnostic difficulties, treatment confusion with COVID-19

Author:: Mark S. Lesney, PhD

Publish date: April 19, 2021

The overall prevalence of CLL and COVID-19 concurrence was around 0.6%, according to the review.

News

Unique oral drug candidate designed to overcome sickle cell disease

Author:: Mark S. Lesney, PhD

Publish date: April 16, 2021

The new drug has shown the ability to stimulate blood cells to produce fetal hemoglobin at levels predicted to...

News

Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patients

Author:: Mark S. Lesney, PhD

Publish date: April 14, 2021

Treatment choices based on new tools such as the Comprehensive Geriatric Assessment can provide useful guidance...

News

Real-world outcomes of caplacizumab for iTTP comparable to clinical trial results

Author:: Mark S. Lesney, PhD

Publish date: April 7, 2021

Real-world evidence from the largest series of TTP patients receiving caplacizumab provides confirmation of the...

News

Risk factors predict graft failure in pediatric acute leukemia patients

Author:: Mark S. Lesney, PhD

Publish date: March 25, 2021

Graft failure is a potentially severe complication in patients treated with allogeneic hematopoietic stem cell...

News

Allo-HSCT plus monoclonal antibody treatment can improve survival in patients with r/r B-ALL

Author:: Mark S. Lesney, PhD

Publish date: March 24, 2021

Transplantation at 4 months after Mab treatment was initiated showed significant benefits in overall and disease...

News

Updated recommendations released on COVID-19 and pediatric ALL

Author:: Mark S. Lesney, PhD

Publish date: March 18, 2021

The main threat to the vast majority of children with acute lymphoblastic leukemia still remains the ALL itself...

Mark S. Lesney, PhD

News

News

News

News

News

News

News

News

News

News

News

News

News

News

News

Pages